Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 11,161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Completed Phase 2 Interventional Results available

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

NCT03257462
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
Interventions
SPR001
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Orange, California • San Diego, California • Melbourne, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 30, 2026, 10:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ascending Glycan Dietary Supplementation in Healthy Adults

NCT04466761
View directory record Official record
Conditions
Healthy Individuals
Interventions
Monosaccharide Powder, Placebo Comparator
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

NCT05647343
View directory record Official record
Conditions
Adverse Effect of Drugs and Medicaments in Therapeutic Use
Interventions
Ciclopirox Olamine Oral, Placebo
Drug · Other
Lead sponsor
Atlas Molecular Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 30, 2026, 10:03 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

An Interventional Study of Infigratinib in Children With Hypochondroplasia

NCT06873035
View directory record Official record
Conditions
Hypochondroplasia
Interventions
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Results available

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

NCT04360174
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
OTX-TIC
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Petaluma, California • Torrance, California • Roswell, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

NCT04657224
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
Interventions
JNJ-64264681, JNJ-67856633
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 4 Interventional

GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study

NCT04473274
View directory record Official record
Conditions
Coronavirus Infection, Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
Samaritan Health Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 30, 2026, 10:03 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

NCT03735290
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
ilixadencel, Pembrolizumab
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 30, 2026, 10:03 PM EDT
Active, not recruiting No phase listed Observational

Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

NCT05319990
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Diabetes Complications, Diabetic Nephropathies, Autoimmune Diabetes
Interventions
Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

NCT03831503
View directory record Official record
Conditions
Healthy Volunteers
Interventions
INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG)
Biological · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 30, 2026, 10:03 PM EDT
Not yet recruiting Phase 2 Interventional

Omadacycline for Treatment Refractory Mycoplasma Genitalium Urethritis

NCT07853742
View directory record Official record
Conditions
Mycoplasma Genitalium Infection, Urethritis
Interventions
Omadacycline Oral Tablet
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 10:03 PM EDT
Completed No phase listed Observational

A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US

NCT04125186
View directory record Official record
Conditions
Nocturnal Polyuria
Interventions
Baseline EpiNP survey, Bladder diary, Testing of EpiNP baseline survey, bladder diary and a qualitative interview, No other intervention
Diagnostic Test · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
10,190 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 30, 2026, 10:03 PM EDT
Completed No phase listed Observational

CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease

NCT02405650
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Obesity
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 79 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT01281150
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

NCT03898791
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LY3295668 Erbumine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Fayetteville, Arkansas • Denver, Colorado • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

NCT00158782
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034, lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 30, 2026, 10:03 PM EDT
Completed No phase listed Observational

Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research

NCT01851382
View directory record Official record
Conditions
Graft vs Host Disease, Healthy Volunteer, Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 30, 2026, 10:03 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Interventions
etakafusp alfa (AB248), pembrolizumab
Biological
Lead sponsor
Asher Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Not applicable Interventional

HOME Study (Health Outcomes and Measures of the Environment Study)

NCT00129324
View directory record Official record
Conditions
Environmental Exposures, Child Development, Lead and Injury Reduction
Interventions
Lead Hazard Control Intervention, Injury Hazard Control Intervention
Procedure
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 30, 2026, 10:03 PM EDT
Terminated Phase 4 Interventional

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

NCT01683188
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
vemurafenib + HD IL-2
Drug
Lead sponsor
Clinigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

NCT02390427
View directory record Official record
Conditions
Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Taselisib, Trastuzumab emtansine, Pertuzumab, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 10:03 PM EDT
Completed No phase listed Observational

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

NCT02319460
View directory record Official record
Conditions
Hemorrhage
Interventions
Kcentra®, Plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
2,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 30, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

NCT04919382
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Temozolomide
Biological · Drug
Lead sponsor
Dwight Owen
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 10:03 PM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

NCT05344482
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 30, 2026, 10:03 PM EDT